Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: Eduardo Canto who wrote (92)	1/20/1998 12:20:00 PM
From: chirodoc	Respond to of 328

<<<<< They haven't started that effort yet, but when they do we will see for the first time Orthovisc and Synvisc going head to head!! ...anyone know when approval/denial/roll out of orthovisc in u.s. is supposed to happen?

To: Eduardo Canto who wrote (92)	1/20/1998 6:27:00 PM
From: John McCarthy	Read Replies (3) \| Respond to of 328

Eduardo - It will really be BMY vs RPR. And RPR has no presense in the market there - thats why I posted the note. It will boil down to this - (1) The Canadians know Synvisc last for 6+ months. (2) So will OV. No product differentiation, so .... (3) Synvisc is in the Universities there - they even offer classes in it (I have the URL's somewhere). (4) BMY (1) Go after the parts of Canada not covered by SYNVISC. These areas are pick-offs. (2) Go after the Universities with $$ for research. Get the schools behind OV. And move Synvisc to background. (5) BMY should wind up with about 70% of the market, unless BIOX fights back with pricing or marketing $$. (6) Note that my link says Synvisc last 7-8 months. OV must approach this. Eduardo, need to know how many Zimmer folks in Canada. I can't find this info anyplace. Finally, I am still a loyal BIOX shareholder. Regards, John